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Introduction
Hepatocellular carcinoma (HCC) represents one of the 
most frequent cause of cancer-related death worldwide, in 
spite of the increasing success in fighting different kinds of 
cancer. 
The poor prognosis of HCC patients is largely attributed 
to tumor phenotypic and genetic heterogeneity, multifocal 
occurrence, high tumor recurrence rate after treatments and 
high predisposition to metastasize (1).
HCC almost always develops on the pathological 
background of a variety of chronic liver diseases, ranging 
from chronic viral hepatitis (hepatitis B and hepatitis C), 
hereditary disorders, alcoholic and chemical injury to 
metabolic syndromes, that contribute to its heterogeneity 
(2). All these chronic liver injuries are able to establish 
environmental changes that directly promote HCC onset, 
maintenance and progression. 
Current therapeutic approaches include surgical 
resection, percutaneous radiofrequency ablation, trans-
arterial chemoembolization and liver transplantation. 
Surgery and local treatments are applicable for patients with 
limited underlying liver disease. However, most patients 
present multifocal HCC and advanced-stage of liver disease 
or comorbidities at the time of diagnosis. Furthermore, 
HCC multifocal occurrence, due to intrahepatic metastatic 
spreading of primary tumor cells or to the development of 
multiple independent HCCs (3), is responsible for frequent 
early phase tumor recurrence following the described 
treatments and largely impacts on their outcome (4). 
Liver transplantation represents the optimal therapy 
allowing to remove both tumor and underlying diseases. 
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However, it is limited by the poor availability of liver donors 
and, consequently, by very long waiting lists, incompatible 
with the severity of the disease; moreover, not all patients 
are eligible for this treatment (5).
Therefore, systemic therapies are clearly needed to 
improve HCC patient’s prognosis. At this regard, the hard 
challenge is performing a therapy protocol taking into 
account the complex alterations that affect the entire organ 
and can largely interfere with most of the currently applied 
therapies making them ineffective (6).
Outline of the current molecular therapies of HCC
Similarly to many other tumors, the development of HCC 
is a multistep process involving the accumulation of genetic 
and epigenetic alterations in regulatory genes, resulting in 
the activation of oncogenes and in the inactivation/loss of 
tumor suppressor genes (7).
Extensive research over the past decade was focused on 
the identification of molecular pathways driving hepatocyte 
transformation, aberrantly activated or expressed, useful for 
early diagnosis and prognosis prediction. Recurrent focal 
amplifications or deletions involving genes that control 
oncogenic or tumor suppressing pathways (i.e., Wnt, 
MAPK, PI3K signaling and p53 pathway) were identified in 
primary HCCs (8). 
Currently, a further effort was made to catalog HCCs 
in subclasses, based on different genetic and epigenetic 
alterations and clinical behavior, with the aim to develop 
tailored treatment strategies. Genomic studies have allowed 
to categorize HCCs into subsets with distinct molecular and 
clinical features. In particular, one subset is characterized 
by altered expression of genes mainly involved in cell 
proliferation (such as mTOR, IGF, Myc and Ras) and 
correlates with an aggressive tumor phenotype. Another 
subset is characterized by activation of the WNT/β-catenin 
and TGFβ signaling pathways (9), known to play a crucial 
role in liver development and liver cell differentiation, 
and found dysregulated in many human cancers. This 
subset is significantly associated to high risk of early tumor 
recurrence. A third subgroup is characterized by altered 
expression of genes involved in interferon signaling and 
inflammation (10). Moreover, increasing efforts enabled 
the identification of a number of HCC-related molecular 
biomarkers, including proteins and non-coding RNAs 
(particularly microRNAs), which role in transformation 
process is yet largely unknown, but which recognition 
could be important to further catalog HCCs and to plan 
diagnostic and therapeutic strategies (11).
At present, the targeted therapies represent the more 
effective treatment of HCC (12). In particular, the multi-
kinase inhibitory sorafenib, was shown to improve the 
overall survival of HCC patients (13,14) with manageable 
toxicity and has become the standard systemic therapy. This 
molecule efficiently inhibits kinase receptors involved in 
the proliferative and stemness pathways found upregulated 
in a variety of human tumors (15). However, for patients 
in advanced-stage of HCC, unresponsive to sorafenib 
or with tumor recurrence, clinical options are yet very 
limited. In these cases, as well as in several other cancers 
unresponsive to the traditional chemotherapy, approaches of 
immunotherapy are promising (16). In particular, a targeted 
therapy of HCC with monoclonal antibodies able to induce 
an activation of the immune system and/or its escape from 
the inhibitory effects of tumor cells has been explored. The 
block of the cytotoxic T lymphocyte-associated antigen 4 
(CTLA-4), which provides inhibitory signals to T cells, 
by means of a monoclonal antibody (tremelimumab), was 
found to lead to cytotoxic T-lymphocyte activation (17,18). 
The monoclonal antibody against the programmed cell 
death-1 (PD-1) receptor on activated T cells (nivolumab) 
was shown to impair its inactivating binding to the ligand 
PDL-1, expressed on HCC tumor cells, thus restoring 
T-cell-mediated antitumor response (19,20). The evaluation 
of efficacy of these immunotherapies in advanced-HCC 
patients in clinical trials (phase II and phase III) is still in 
progress. 
Additional ongoing trials have been designed to test 
drugs in biomarker-based HCC subpopulations (21).
Lessons from phase III clinical trial
After the completion of a number of phase III clinical 
trials of patients with advanced HCC, appeared clear that 
targeted agents other than Sorafenib do not significantly 
improve the overall survival, and that combination therapies 
do not show significant advantage (22). 
A part of the reason for the failure of these treatments 
resides in the HCC heterogeneity, together with an 
unsatisfactory classification, that reduces the efficacy of 
therapeutic protocols directed to a single target. Moreover, 
the liver toxicity of several compounds (a limiting feature 
in patients with pre-existing liver pathologies) and 
the marginal anti-tumor effects of tools utilized so far 
contributed to the disappointing results of phase III clinical 
trials (22).
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The strong recurrence of the tumor after chemical/
immune therapy or surgical eradication suggests a relevant 
role of liver progenitors or cancer stem cells (CSCs) in the 
reappearance of the disease. Whatever the origin of HCC, 
from mutations in normal stem cells or from events of 
reprogramming of differentiated hepatocytes, the presence 
of cancer cells with stemness features renders the therapies 
less effective (due to chemo-resistance, increased survival, 
resistance to hypoxia, immuno-tolerance, active drug-
exporting systems observed in these cells) (23). CSC-
targeted treatments would have potential high benefit 
at long-term ensuring the eradication of the cell subset 
responsible for the maintenance of tumor mass. 
Notably, the acquisition or the maintenance of stemness 
features by pre-neoplastic and neoplastic cells can derive, 
other than from cell genetic/epigenetic modifications, also 
from tumor microenvironmental stimuli (e.g., extracellular 
matrix (ECM)-driven inputs, selective signals induced by 
treatments such as chemotherapy). Hence, specifically 
targeting these favorable tumor micro-environmental 
elements may increase the efficacy of therapies.
Altogether, the features of the HCC described so far 
underline how in the treatment of this tumor it is necessary 
to consider several aspects, including genetic and epigenetic 
alterations of each HCC, the persistence and the role of 
CSCs and, non-last, the tumor environment that favors 
both the development and the progression of the cancer and 
the reduction of current therapy efficacy. Therefore, new 
therapeutic approaches should aim to combine antitumor 
efficacy with “normalizing” effects on the environment 
where HCC develops with the final goal to reduce both cell-
autonomous and non-cell autonomous oncogenic stimuli, 
to render more accessible to the drugs the transformed cells 
and, ultimately, to reduce cancer recurrence after treatment. 
Now, we will analyze the cellular, chemical and physical 
aspects of the microenvironment influencing the crosstalk 
between cells and tumor niche to indicate possible 
therapeutic targets and tools.
Role of microenvironmental cues in HCC 
pathogenesis
HCC development is commonly associated with pre-
existing chronic liver diseases representing high risk 
factors (viral, alcoholic, toxic and metabolic liver hepatitis). 
Whatever the etiology, the tumor pathogenesis is invariably 
related to inflammation process, high rate of hepatocyte 
death and regenerative proliferation and activation of 
hepatic stellate cells (HSCs) into fibril-producing cells. 
All these conditions, leading to liver fibrosis, are highly 
predisposing to tumor onset and favor tumor progression 
and metastasization (intraorgan and/or at distance).
Therefore, it is now clear that HCC development is 
strictly dependent on environmental cues able to induce 
and maintain biological changes in tumor cells and in 
their tissue niche. The main cellular components of HCC 
microenvironment are stromal cells [including carcinoma-
associated fibroblasts (CAFs)], endothelial cells, HSCs and 
immune cells [including tumor-associated macrophages 
(TAMs)]; all of them are influenced by the molecular 
interplay (modulated via growth factors, inflammatory 
cytokines, ECM proteins and cell-cell contacts) with the 
other ones (24). 
In this section, we will discuss the main micro-
environmental changes triggered by chronic liver damage 
that on one hand is a source of hepatocyte proliferative 
stimuli and, on the other one, induces progressive stromal 
alteration. Taking these changes into account will allow the 
acquisition of better knowledge of the mechanisms involved 
in tumor occurrence and the set-up of more effective 
therapeutic approaches. 
Liver inflammation as driving force of liver cell 
transformation 
HCC is strictly related to the inflammation process (25). 
The recruitment of inflammatory cells in the chronically 
injured tissue, indeed, is crucial for the microenvironment 
changes driving to fibrosis and HCC insurgence.
Infected or in various ways injured parenchymal cells 
secrete a variety of cytokines, including interleukin-1β (IL-
1β), tumor necrosis factor α (TNFα), transforming growth 
factor β (TGFβ) and interleukin-6 (IL-6), responsible 
for the recruitment and the activation of other cell types. 
Among these cells, fibrogenic cells (mainly HSCs) are 
activated; this leads to the production of an excessive 
amount of ECM proteins that, in turn, altering stroma 
composition and stiffness, are responsible for further 
activation of HSCs and recruitment of inflammatory cells, 
effectively establishing a positive pathogenic loop (Figure 1).
IL-1β is an inflammatory cytokine released from 
infiltrating macrophages during liver chronic inflammation 
and contributing to the establishment of fibrosis (26). 
TNFα, produced by inflammatory and endothelial cells, 
induces hepatocyte survival and resistance to apoptotic 
stimuli, so having an important role in promoting HCC (27).
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IL-6, mainly released by resident liver macrophages 
(Kupffer cells) early after hepatocyte damage or by hepatitis 
virus infected hepatocytes (28,29), has been found at 
high serum level in chronic liver diseases and correlates 
with an increased risk to develop HCC (30). This well-
known inflammatory cytokine activates and maintains 
liver inflammation as well as tumor-associated signaling 
pathways, leading to hepatitis progression, hepatocyte 
continuous proliferation, cirrhosis and ultimately HCC. 
When tumor has arisen, IL-6 is secreted by infiltrating 
TAMs and promotes the expansion of HCC progenitor/
CSCs; its high plasma level, in fact, correlates with tumor 
recur rence, metastasis and poor prognosis (31,32). 
Among the cytokines secreted by inflammatory cells, 
the TGFβ represents one of the most relevant pro-
fibrogenic molecules, responsible for HSCs activation and 
consequently synthesis and secretion of high amount of 
ECM proteins (33). Moreover, the cytokine induces the 
differentiation and function of CAFs (34).
The establishment of an inflammatory response is a 
common aspect of chronic viral hepatitis, the most frequent 
risk factor of HCC. About three-quarters of HCCs 
worldwide are ascribed to chronic hepatitis B virus (HBV) 
and hepatitis C virus (HCV) infections (35). HCV infection, 
in particular, is one of the main causes of chronic liver 
disease, in most Western countries, leading to liver fibrosis, 
cirrhosis and HCC (36). HCV has been strongly implicated 
in HCC pathogenesis because of its role in the alteration 
of ROS and other signaling pathways and in modulation 
of immune responses and apoptosis (36,37). On the other 
hand, infection creates an inflammatory environment, 
elevating IL-1β levels and altering TGFβ signaling (38). 
The continuous inflammation in infected liver cells, in fact, 
induces alternating cycles of cell elimination by apoptosis 
and tissue regeneration contributing to the long-term 
establishment of fibrosis.
Over the last years, a combination of direct-acting 
antiviral drugs (DAAs) has been very effective in eradicating 
HCV and inhibiting continuous inflammation in the 
liver. However, treating HCV infection is not sufficient to 
ameliorate existing liver diseases, such as advanced cirrhosis, 
and to protect against HCC development (39). Also, the 
incidence of HCC after HCV clearance is still very high in 
those patients and complicated by concomitant risk factors 
(e.g., HBV co-infection or metabolic syndromes) suggesting 
that the viral infection can leave a “mark” in liver cells or 
in liver microenvironment favoring the establishment/
promotion of liver cancer. Importantly, wide range analysis 
of gene expression in HCV-infected livers at early stage 
of cirrhosis, unveiled a 186-gene signature that was able 
to predict cirrhosis progression and HCC insurgence. 
Marker genes that defined the signature were enriched in 
inflammation signals, including the NF-kB pathway and 
IL-6 signaling (40).
Fibrosis as tumor promoting background
Fibrosis represents an invariable evolution of chronic 
inflammatory processes, and its pathological endpoint, 
cirrhosis, a high-risk factor for the occurrence of HCCs.
Fibrosis is characterized by a deregulated remodeling of 
ECM, consisting in an increased deposition and a reduced 
turnover of its components. ECM accumulation not only 
causes deeply changes in liver architecture and function 
but can also create a physical barrier to drug delivery. The 
main fibrogenic cells are HSCs while the contribution 
of parenchymal cells (hepatocytes and cholangiocytes 
undergoing epithelial-to-mesenchymal transition, EMT), of 
endothelial cells (undergoing endothelial-to-mesenchymal 
transition) and of bone marrow stem cells, which has also 
been described (41), appears to be at lesser extent.
HSCs secrete ECM proteins, metalloproteinases (MMPs) 
and their tissue specific inhibitors (i.e., TIMPs), together 
with a lot of cytokines, including platelet-derived growth 
factors (PDGFs), fibroblast growth factors (FGFs), vascular 
endothelial growth factor (VEGF) and TGFβ. All of these 
contribute to sustain and increase the fibrotic process 
and, when the hepatocyte transformation has occurred, to 
positively promote the proliferation and survival of tumor 
cells (42). 
Activation
Inflammation
Hepatocyte Fibroblast-like cell
CAF
EMT 
proliferation 
transformation
HSC
Myofibroblast
Fibrosis
Figure 1 Cell-cell and cell-stroma interplay sustaining fibrosis and 
inducing hepatocyte transformation. HSC, hepatic stellate cell; 
CAF, cancer activated fibroblast; EMT, epithelial-to-mesenchymal 
transition.
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Fibrotic microenvironment, moreover, is characterized by 
increased stiffness of the entire organ that, while affects liver 
cell proliferation, differentiation state, functionality (43) 
and sensitivity to the drugs, further promotes activation 
of quiescent HSCs, establishing a positive feedback loop, 
responsible for the formation of pathological scar tissue and 
then cirrhosis (44) (Figure 1).
While the late stages of liver fibrosis and cirrhosis are 
irreversible, the early stages of fibrosis and, possibly, of 
cirrhosis are to some extent reversible (45). Thus, the 
development of strategies targeting liver fibrosis could stop 
the progression of disease.
Finding new molecular targets
Inflammation and fibrosis are processes largely investigated 
and most of the molecular mechanisms have been clarified. 
The dissection of molecular pathways driving to and/
or activated by these pathological situations and directly 
involved in HCC initiation and development, permits 
to identify molecular targets for innovative therapeutic 
protocols.
Hippo/yes-associated protein (YAP) pathway
Hippo pathway is a molecular signaling starting from 
several extracellular signals, including diffusible molecules 
and mechanical stimuli, all parameters strongly altered 
in fibrotic livers. Hippo signaling consists of a specific 
and evolutionary conserved set of kinases, such as 
Hippo/MSTs and LATS1/2 (46), largely converging on 
YAP, a co-transcriptional factor responsible for a wide 
modulation of gene expression. Activation of Hippo 
pathway results in YAP inhibitory phosphorylation and 
degradation and, ultimately, in the inactivation of the 
YAP-dependent transcriptional activity (46). The Hippo/
YAP signaling in the liver controls development, mass 
homeostasis, ECM composition and elasticity, hepatocyte 
proliferation and differentiation, as well as the maintenance 
of stem/precursor compartments. Its dysregulation, by 
inactivation of Hippo kinases and/or activation of YAP, 
has been observed in several human cancers and has been 
experimentally demonstrated to have a significant impact on 
cancer development, both by eliciting microenvironment 
changes triggering fibrosis and promoting tumor onset (47). 
YAP, in fact, can influence the chemical and physical 
composition of the tumor microenvironment through 
the functional regulation of different cell types. This 
function is mainly accomplished through the regulation of 
HSCs, where YAP induces the secretion of ECM and pro-
angiogenetic proteins (48). YAP function is required for the 
establishment and maintenance of CAFs (49). Moreover, 
YAP stimulates the production of chemoattractants for the 
recruitment of T cell suppressing myeloid-derived cells 
by carcinoma cells (50). YAP hyperactivation can promote 
tumorigenesis through the stimulation of proliferation, 
reduction of cell death and expansion of stem cell/precursor 
populations (51,52). At the same time, the reactivation of 
YAP in differentiated hepatocytes (where it is normally 
inactive) can induce their de-differentiation (52) and 
the acquisition of mesenchymal traits, thus triggering 
cell migration and invasion and conferring chemo-
resistance (53). Diethylnitrosamine (DENA)-induced liver 
tumorigenesis in rat models showed an early accumulation 
of YAP in pre-neoplastic foci and in oval cells, promoting 
their tumorigenic and metastatic properties (54), thus 
indicating YAP as a sensitive marker of pre-neoplastic 
stages. 
Accordingly with the role of YAP in HCC development, 
its increased expression and nuclear localization have 
been observed in more than 85% of adult HCC tumor 
samples (55), and in 62% of patients with HBV-associated 
HCC after surgical liver resection (56). Furthermore, 
its overexpression has been significantly associated with 
a poor prognosis of HCC patients (tumor recurrence, 
shorter overall survival and lower disease-free survival after 
treatment) resulting an independent prognostic marker for 
HCC (56,57).
Other than genetic alterations of Hippo pathway 
components, microenvironmental cues can control YAP 
subcellular localization and activation. Mechanical inputs 
from ECM, such as matrix stiffness and cytoskeletal 
tension, represent a crucial trigger for nuclear localization 
and transcriptional activation of YAP (58). When resident 
liver stem cells are cultured on stiff ECM, YAP is retained 
in the nucleus in the active form, whereas it is inhibited 
and re-localized in the cytoplasm when the same cells are 
cultured on a soft ECM (43). Interestingly, YAP subcellular 
localization correlates with differentiation state of liver 
cells, such as of several other cell types (43,58). Moreover, 
culturing HSCs on soft substrates inhibits YAP signaling 
and cell activation that, instead, occurs when HSCs are 
cultured in high stiffness (48).
In vivo, the altered stiffness of the inflamed/fibrotic 
liver can represent a major trigger of YAP activation 
for hepatocytes (as well as for HSCs), that therefore go 
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towards de-differentiation and proliferation. The same de-
differentiative and proliferative stimuli can be exerted by 
rigid stroma also on transformed hepatocytes so influencing 
tumor progression. These findings, while explain why 
chronic liver diseases can increase the risk of HCC, support 
the need to take into account microenvironment changes in 
the design of new strategy for tumor eradication. Since YAP 
activation, as said above, may influence and be influenced by 
the composition and the chemical/physical characteristics of 
the tumor microenvironment, the targeting of this pathway 
could represent an efficient approach to “normalize” both 
tumor cells and tumor niche.
Targeting of YAP 
The described role of YAP in the pathogenesis of HCC 
suggests YAP as a possible therapeutic target for the 
treatment of HCC. Several observations in animal 
models demonstrated the efficacy of YAP silencing in 
the prevention and regression of liver fibrosis and in the 
reduction of experimentally induced liver cancers; this 
suggests that genetic or pharmacological interference of 
YAP expression/activity could provide therapeutic benefits 
in humans. 
In the last few years, different approaches to inhibit YAP 
oncogenic function have been proposed. A pharmacological 
inhibitor of YAP activity, verteporfin, has been recently 
identified by a drug library screening for the ability to 
interfere with YAP-dependent transcription (59). It is 
a small molecule able to selectively bind YAP and, by a 
conformational change, to impairs its interaction with its 
transcriptional factor TEAD. TEAD factor, in fact, is essential 
in mediating YAP-dependent gene expression leading to cell 
proliferation, oncogenic transformation and EMT (59,60).
Verteporfin appears an ideal drug for selective 
inhibition of YAP-induced tumorigenesis. Its experimental 
administration in rats and mice, in fact, has been shown to 
inhibit the YAP oncogenic activity (54,59) without affecting 
liver size and safety of wild-type animals (59). Moreover, 
it has been shown that verteporfin interferes with the high 
stiffness-dependent HSC activation in vitro and ameliorates 
the CCl4-induced liver fibrosis in vivo (48,61). Notably, 
phase I/II clinical trials in pancreatic cancer reported a safe 
utilization of the drug (62), suggesting a feasible application 
to HCC treatment. 
Approaches using small peptides to inhibit YAP function 
through competition with TEAD interaction have been also 
described. The use of cyclic peptides mimicking the binding 
of YAP to TEAD significantly reduced HCC growth rate 
in mice (63). Moreover, a small peptide consisting in the 
inhibitory domain of the vestigial-like protein 4, a natural 
antagonist of YAP in TEAD binding, has been successfully 
assessed in the suppression of gastric cancers in vivo (64). 
In addition, an engineered TEAD-dominant negative 
protein, lacking its DNA-binding domain, has been shown 
to suppress YAP-mediated transactivation and to prevent 
YAP-driven tumorigenesis (59). Notably, these pre-
clinical studies have also demonstrated that the TEAD-
dominant negative can inhibit liver tumorigenesis caused 
by YAP overexpression without compromising normal liver 
homeostasis and physiology (59); this suggests that YAP 
pathway targeting can ensure high selectivity for cancer 
cells, compared to conventional therapies. 
Direct targeting of YAP has been performed also by 
using small interfering RNA encapsulated into lipid 
nanoparticles (siRNA-LNPs); this treatment reduces tumor 
cell proliferation, restores hepatocyte differentiation and 
zonal gene expression, eventually causing tumor regression 
in mice models of advanced HCC (65). The only mild and 
reversible side effects observed in treated animals encourage 
clinical application.
Altogether, these results render YAP pathway a promising 
target for molecular therapy of HCC.
TGFβ signaling
The pleiotropic TGFβ cytokine has emerged as a pivotal 
player in HCC pathogenesis and progression, arranging 
microenvironment and cell autonomous changes, both 
favorable for tumor onset and growth (66). 
The TGFβ signaling pathway involves the binding of the 
cytokine to a serine-threonine kinase type II receptor (TGFβ 
RII) that recruits and phosphorylates a type I receptor 
(TGFβ RI). The TGFβ RI subsequently phosphorylates 
downstream effectors, typically Smad transcription factors 
(Smad-dependent pathway). Moreover, TGFβ can signal 
in a Smad-independent manner, integrating pathways 
starting from a variety of extracellular signals and adhesion 
molecules, thus inducing a complex modulation of gene 
expression (67). 
TGFβ signaling is involved in all stages of HCC 
progression, from initial liver injury and inflammation 
through fibro/cirrhosis to tumor initiation, development 
and metastasis.
TGFβ has cytostatic, apoptotic and aging effects 
in hepatocytes during embryogenesis, controls mass 
homeostasis and suppresses tumor development at early 
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stages in adults (68). On the contrary, high level of the 
cytokine or an upregulation of its pathway promotes liver 
inflammation, fibrosis, activation of HCSs and, when the 
transformation process had occurred, the apoptosis resistance 
and proliferation of transformed hepatocytes (68). Moreover, 
TGFβ is a major inducer on EMT, thus promoting 
progression and metastasis of primary tumors (69).
TGFβ is synthesized and secreted by inflammatory cells 
and, while stimulates the activation of HSCs into fibrogenic 
cells, it is produced and secreted by these. Moreover, 
hyperactivation of its signaling in tumor cells can derive from 
autocrine loop, other than from paracrine mechanisms (70,71). 
Tumor-secreted TGFβ may reduce antitumor immune 
responses by increasing the quantity of immunosuppressive 
cells, such as regulatory T cells (72,73), and may regulate 
the production/secretion of growth factors and cytokines 
by CAFs, thus contributing to tumor cell proliferation and 
invasion, and to neoangiogenesis (34). 
Accordingly with its tumor promoting role, the TGFβ 
signaling was found constitutively activated in HCC cell 
lines (74,75). Moreover, high serum levels of the cytokine 
were found in advanced-stage HCC patients and correlated 
with tumor vascularization, metastasis formation, reduced 
survival and poor prognosis (75-78). 
Targeting of TGFβ signaling 
As described above, the presence of TGFβ signaling is 
not restricted to late stages of HCC but it is observed 
throughout the development of HCC, working at different 
levels during HCC pathogenesis in an autocrine/paracrine 
manner. It can modulate both cancer cell function and 
microenvironment changes, and its inhibition can affect 
different stages of HCC onset and progression and offer a 
wide therapeutic application.
Specific TGFβ-receptor inhibitors have been developed 
and utilized in preclinical models to test their efficacy 
as anti-fibrotic and anti-cancer tools. The in vitro 
characterization of these inhibitors showed anti-EMT 
effects with re-expression of E-cadherin (79). In vivo, it has 
been observed a reduced fibro-cirrhotic process, inhibition 
of neoangiogenesis due to a block in the VEGF production 
(71) and a reduced migration and invasion of HCC cell 
lines (79). In particular, the orally active TGFβ RI/II kinase 
dual inhibitor LY2109761, has been proven effective in the 
reduction of vascular invasion (79) and in the inhibition 
of tumor growth and metastasis in xenograft model of 
HCC (80). Another TGFβ-receptor inhibitor, LY2157299 
monohydrate (Galunisertib) (81), is now under clinical 
evaluation in phase II clinical trials and suggests improved 
clinical outcome in patients with HCC (82). 
EMT-driving signaling pathways
EMT is a trans-differentiation process involving a deep 
reprogramming of the cellular transcriptional profile, 
leading to the loss of polarity and cell-cell contacts and the 
acquisition of a mesenchymal phenotype and migratory 
capacity. EMT is dynamically regulated in physiological 
background where it is reversible [in mesenchymal-to-
epithelial transition (MET)] (83).
The EMT/MET dynamics characterizes physiological 
situations, such as organogenesis during embryonic 
development, wound healing and tissue regeneration in the 
adult, but it also drives pathological states, including fibrosis 
and epithelial tumor progression (84). 
In the liver, several tissue conditions and diffusible 
molecules can induce EMT program. Major role in its 
activation is played by the mechano-stimuli starting from 
high rigidity of the fibrotic stroma and by the cytokines, 
primarily TGFβ, influencing tumor microenvironment and 
tumor cells.
While the contribution to the fibrogenesis of normal 
hepatocytes induced in EMT is still debated (85), the 
relevance of EMT in transformed hepatocytes during tumor 
progression is well established. In particular, cells lose 
epithelial differentiation and possibly acquire self-renewal 
ability and stemness gene expression. The occurrence of 
an EMT program in a tumor cell induces the acquisition 
of more aggressive properties, including motility and 
invasivity, increased resistance to apoptotic stimuli and 
chemoresistance (86). 
Various master factors, mainly acting as transcriptional 
repressors of epithelial genes, were shown to be sufficient to 
trigger and orchestrate EMT. In particular, Snail is sufficient 
to induce EMT in vitro in many epithelial cells, and its over-
expression in vivo correlates with drug resistance, metastasis, 
high risk for recurrence and poor prognosis (87-89). Snail 
has been shown to negatively regulate a plethora of genes 
ranging from adhesion molecules (mainly E-cadherin), pro-
apoptotic genes (e.g., Bid and p53), cytoskeletal molecules 
(e.g., cytokeratins) to master genes of epithelial/hepatocytes 
differentiation (i.e., HNF4α and HNF1α, see below) 
through the direct binding to their promoters and the 
subsequent transcriptional repression (90-93). 
Furthermore, Snail, through the transcriptional 
repression of miRNAs can upregulate mesenchymal 
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markers, survival genes, genes involved in cell movement 
and invasion (e.g., MMPs) and stemness genes (94). 
EMT transcriptional master regulators appear sufficient 
to reprogram differentiated cell towards an alternative 
identity thanks to their ability to deeply impact the 
chromatin state by directly recruiting chromatin modifiers 
to specific genes. Recent evidence revealed that Snail 
repressive activity, pivotal in EMT onset and maintenance, 
depends on upregulation and recruitment on the promoters 
of target genes of repressive chromatin modifiers. In 
particular, Snail recruits the histone demethylase LSD1 
(95) and the member of Polycomb group proteins EZH2 
(93) and up-regulates DNA methyl transferases by 
downregulating their inhibitory microRNA (96). Notably, 
Snail/EZH2 complex requires the enrolment of the long 
non-coding RNA HOTAIR, previously indicated by in vivo 
studies as an excellent predictor of metastasis and tumor 
recurrence in HCC (97,98). Accordingly, recent evidence 
revealed that genome-wide epigenetic modifications are 
required for the execution of EMT program (99) and are 
extensively involved in the development of HCC (100).
Targeting of EMT program
Strategies to counteract EMT in tumor progression were 
largely investigated. One kind of therapeutic approach 
consists in an epigenetic cancer therapy targeting 
chromatin regulators involved in EMT. Different classes 
of drugs, including histone deacetylase inhibitors, DNA 
methyltransferase inhibitors or demethylating agents (i.e., 
5-azacytidine) have been utilized both in HCC cell lines 
and in xenograft models showing reduced cell proliferation 
and survival, and inhibition of tumor growth (101). 
Furthermore, highly specific EZH2 and LSD1 inhibitors 
have been developed and currently utilized in clinical trials 
for cancer of different origins (102,103). This strategy has 
not yet applied in vivo to HCC. 
Others therapeutic approaches aimed at directly 
interfering with the functional role of Snail can be pursued, 
for example, by using Snail dominant-negative mutants or 
the expression of Snail repressors able to drive genetic and 
epigenetic reprogramming of tumor cells. One of these 
master tumor suppressors will be described in the next 
section.
Targeting of oncogenic function of lncRNAs such as 
HOTAIR, already prognostic biomarker for different kind 
of cancers (104), can also represent a promising strategy for 
EMT impairment in HCC (105).
Unbiased molecular tools: the case of 
hepatocyte nuclear factor 4α (HNF4α)
A major challenge in cancer research is the identification of 
therapeutic strategies able to selectively target cancer cells 
without affecting normal cells.
A possible approach for HCC treatment that can be 
conceived is the genetic and epigenetic cell reprogramming 
through the delivery of master transcription factors.
HNFs are transcription factors that, cooperatively, are 
responsible for the maintenance of differentiation and 
metabolic functions of hepatocytes (106). In particular, 
HNF4α was shown to maintain hepatocyte identity by 
activating epithelial/hepatocyte genes (107,108) and by 
repressing the expression of mesenchymal genes (109). 
The high number of target genes revealed by genome-scale 
studies (110) demonstrated that HNF4α is a wide-range 
regulator of liver gene expression.
In human liver, HNF4α expression was found to be 
reduced in fibro-cirrhotic tissues and decreased in tumor 
tissue compared to the non-tumoral one of the same 
patients (111,112). Reduction/loss of HNF4α was found in 
about 70% of HCC, also not associated with hepatitis virus 
infection (111). The impaired HNF4α expression correlates 
with poor differentiation, metabolic defects and altered 
liver architecture, with metastatic potential of neoplastic 
cells and, ultimately, with an unfavorable outcome in HCC 
patients (111).
Several liver injuries target HNF4α (113) and lead to 
significant changes in its expression or DNA binding (114-117).
In this context, it has been reported that genes sensitive 
to HNF4α knock-down significantly overlap genes affected 
by inflammatory cytokines (118), supporting the hypothesis 
that HNF4α is involved in regulating the inflammatory 
response in the liver.
A recent report showed that transient inhibition of 
HNF4α activates an inflammatory feedback loop triggering 
and sustaining hepatocellular transformation (119). In 
particular, in this study, HNF4α was found to repress 
the IL-6/STAT3 inflammatory pathway. Interestingly, 
perturbation of this circuit has been also observed in human 
HCC tissues at different stages of HCC pathogenesis 
(earlystage and advanced stage), supporting a functional role 
of HNF4α in the inflammation-related HCC.
Loss of hepatocyte differentiation and reduced levels 
of HNF4α have been observed also upon pathological 
stimuli from microenvironment (i.e., ECM high stiffness, 
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reminiscent of a liver fibro-cirrhotic state; presence of 
TGFβ) (43,120,121) and viral infection (122,123) and 
associated to several tumor-related properties such as 
chemoresistance, strong proliferative response and EMT 
(112,122,124) (Figure 2).
The pivotal role of HNF4α protein as tumor suppressor 
suggested the design of therapeutic approaches based on the 
restoration of its expression and function in HCC.
Several evidences supported the use of HNF4α as “drug” 
for HCC treatment. The advantage of this kind of approach 
resides first of all in the possibility to target tumor cells 
independently of their origin (transformed hepatocytes 
in EMT or liver CSCs). Secondly, the wide-range tumor 
suppressing activity of HNF4α allows the simultaneous 
targeting of several cellular tumor-related properties 
(Figure 3). In particular, extensive in vivo studies demonstrated 
that HNF4α restores hepatocyte differentiation and induces 
MET in HCC cell lines (109), controls the epigenetic state 
of differentiated hepatocytes through the down-regulation of 
DNA methyltransferases (96), interferes with the expression 
of EMT-master genes through their direct transcriptional 
repression (109) and with the expression of stemness markers 
through the upregulation of the epithelial miRNAs 200s and 
34a (94).
Finally, the restoration of HNF4 expression/activity can 
“normalize” tumor microenvironment ameliorating hepatic 
fibrosis in rats (125) and reducing hepatic inflammation 
(116). 
Accordingly with these observations, HNF4α delivery 
in pre-clinical models resulted in the impairment of HCC 
occurrence and in the reduced growth of established tumors 
(112,126,127).
However, recent data showed that the HNF4α capability 
to restore a more differentiated phenotype and a less 
aggressive behavior in transformed hepatocyte could be 
impaired in the presence of TGFβ, thus suggesting that the 
therapeutic use of HNF4α gene delivery could be limited 
by a TGFβ-containing tumor environment. In particular, 
TGFβ signaling appeared responsible of several post-
translational modifications able to interfere with the binding 
of HNF4α to its target genes, including mesenchymal genes 
normally suppressed by HNF4α (120). In this context, 
efforts are required to identify the inactivating post-
translational modifications induced by TGFβ on HNF4α 
and consequently, to engineer mutants insensitive to the 
inactivating action of the cytokine.
Interestingly, in the last few years other members of 
HNF family have been described as tumor suppressors in 
HCC and their restoration produced successful results in 
terms of treatment of fibrosis and cancer in pre-clinical 
studies (128). Focusing also on these proteins as tools for 
molecular therapy of HCC can be a promising challenge for 
the future. 
HNF4α
Viral infection  
(e.g., HBV and HCV)
Inflammation 
(e.g., IL-6)
Fibrosis/cirrhosis 
(e.g., ECM stiffness)
EMT inducers 
(e.g., TGFβ)
Cell proliferation
Chemoresistance
Survival
EMT
HSC activation
Invasion and 
metastasis
De-differentiation 
and stemness
Impaired liver 
architecture
Metabolic defects
Figure 2 Deregulation of HNF4α in hepatocytes during HCC 
pathogenesis. Signals from microenvironment responsible for 
a reduced/loss of HNF4α expression/activity were shown and 
correlated to tumor-associated outcomes. See text for references. 
HNF4α, hepatocyte nuclear factor 4α; HSC, hepatic stellate cells; 
HCC, hepatocellular carcinoma; EMT, epithelial-to-mesenchymal 
transition; IL-6, interleukin 6; HBV, hepatitis B virus; HCV, 
hepatitis C virus; ECM, extracellular matrix; TGFβ, transforming 
growth factor β.
HNF4α 
restoration
EMT
HSC activation
CSC generation
Inflammation
ECM-induced signaling
Cell proliferation
Epithelial/hepatocyte 
differentiation
Figure 3 Potential tumor suppressor effects of HNF4α restoration/
delivery in HCC. See text for references. HNF4α, hepatocyte 
nuclear factor 4α; HCC, hepatocellular carcinoma; HSC, hepatic 
stellate cells; EMT, epithelial-to-mesenchymal transition; ECM, 
extracellular matrix; CSC, cancer stem cells. 
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Conclusions
As highlighted from recent literature and outlined in this 
review, the complexity of cellular and microenvironmental 
networks influencing efficacy of current systemic molecular 
therapies needs to be taken into account for a successful 
management of HCC. Further characterization of cell-cell 
and cell-stroma interplay in livers with HCC will contribute 
to the design of novel and more efficient therapeutic 
approaches.
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